Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Feyfant

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Mabs|March 21, 2026
Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutionsJohn C Shelley, Qing Chai, Lina Wu, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 25, 2016
Peripheral Administration of a Long-Acting Peptide Oxytocin Receptor Agonist Inhibits Fear-Induced FreezingMeera E Modi, Mark J Majchrzak, Kari R Fonseca, et al.
Chemical Biology & Drug Design|July 16, 2010
A protein relational database and protein family knowledge bases to facilitate structure-based design analysesDominick Mobilio, Gary Walker, Natasja Brooijmans, et al.
Science Signaling|November 16, 2017
Generation of specific inhibitors of SUMO-1- and SUMO-2/3-mediated protein-protein interactions using Affimer (Adhiron) technologyDavid J Hughes, Christian Tiede, Natalie Penswick, et al.
Journal of Medicinal Chemistry|July 13, 2023
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical DevelopmentVincent Guerlavais, Tomi K Sawyer, Luis Carvajal, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2009
Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitorsDarrin W Hopper, Matthew D Vera, David How, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2014
A general approach to site-specific antibody drug conjugatesFeng Tian, Yingchun Lu, Anthony Manibusan, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2013
Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapyYong S Chang, Bradford Graves, Vincent Guerlavais, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Mabs|March 21, 2026
Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutionsJohn C Shelley, Qing Chai, Lina Wu, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 25, 2016
Peripheral Administration of a Long-Acting Peptide Oxytocin Receptor Agonist Inhibits Fear-Induced FreezingMeera E Modi, Mark J Majchrzak, Kari R Fonseca, et al.
Chemical Biology & Drug Design|July 16, 2010
A protein relational database and protein family knowledge bases to facilitate structure-based design analysesDominick Mobilio, Gary Walker, Natasja Brooijmans, et al.
Science Signaling|November 16, 2017
Generation of specific inhibitors of SUMO-1- and SUMO-2/3-mediated protein-protein interactions using Affimer (Adhiron) technologyDavid J Hughes, Christian Tiede, Natalie Penswick, et al.
Journal of Medicinal Chemistry|July 13, 2023
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical DevelopmentVincent Guerlavais, Tomi K Sawyer, Luis Carvajal, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2009
Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitorsDarrin W Hopper, Matthew D Vera, David How, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2014
A general approach to site-specific antibody drug conjugatesFeng Tian, Yingchun Lu, Anthony Manibusan, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2013
Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapyYong S Chang, Bradford Graves, Vincent Guerlavais, et al.
Pageof 2